Unveiling Incyte (INCY) Q4 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 02/05/26
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)Business Wire • 01/30/26
Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 01/12/26
This Biotech Stock Eyes Fresh Entry With 522% Earnings Growth SeenInvestors Business Daily • 01/09/26
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line LymphomaZacks Investment Research • 01/06/26
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell LymphomaBusiness Wire • 01/05/26
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular LymphomaBusiness Wire • 12/22/25
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal CancerBusiness Wire • 12/22/25
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular LymphomaBusiness Wire • 12/17/25